MedPath

Jiangsu Province Hospital (The First Affiliated Hospital With Nanjing Medical University)

🇨🇳China
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

441

Active:10
Completed:71

Trial Phases

6 Phases

Early Phase 1:11
Phase 1:25
Phase 2:103
+3 more phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (331 trials with phase data)• Click on a phase to view related trials

Not Applicable
145 (43.8%)
Phase 2
103 (31.1%)
Phase 4
28 (8.5%)
Phase 1
25 (7.6%)
Phase 3
19 (5.7%)
Early Phase 1
11 (3.3%)

Efficacy and Safety of Minimally Invasive D2+PAND Gastrectomy for Gastric Cancer With PAN Metastasis After Conversion Immunochemotherapy

Not Applicable
Recruiting
Conditions
Gastric Cancer
First Posted Date
2025-07-09
Last Posted Date
2025-07-09
Lead Sponsor
The First Affiliated Hospital with Nanjing Medical University
Target Recruit Count
30
Registration Number
NCT07056010
Locations
🇨🇳

First Affiliated Hospital of Nanjing Medical Unviersity, Nanjing, Jiangsu, China

A Multicenter Prospective Randomized Controlled Clinical Trial Comparing Constant (5%) Versus Sequential (5%-2%) Oxygen Concentration Embryo Culture Protocols in Assisted Reproductive Technology

Not Applicable
Recruiting
Conditions
Blastocyst IVF
Fertility Issues
Embryo Culture
First Posted Date
2025-07-03
Last Posted Date
2025-07-03
Lead Sponsor
The First Affiliated Hospital with Nanjing Medical University
Target Recruit Count
980
Registration Number
NCT07050537
Locations
🇨🇳

The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China

🇨🇳

Changzhou Maternal And Child Health Care Hospital, Changzhou, Jiangsu, China

🇨🇳

Nanjing Women and Children's Healthcare Hospital, Nanjing, Jiangsu, China

and more 2 locations

Omega-3 Supplementation and Immunotherapy in Gastric Cancer: A Phase II Trial

Not Applicable
Not yet recruiting
Conditions
Gastric Cancer Stage III
Interventions
Dietary Supplement: Omega-3 Supplementation
Drug: Neoadjuvant Immunotherapy
First Posted Date
2025-07-03
Last Posted Date
2025-07-03
Lead Sponsor
The First Affiliated Hospital with Nanjing Medical University
Target Recruit Count
80
Registration Number
NCT07050524
Locations
🇨🇳

First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China

The Risk Factors Related to Rupture Flow-related Aneurysms in Posterior AVM

Recruiting
Conditions
Arteriovenous Malformation of Central Nervous System
Aneurysm, Ruptured
Aneurysm Cerebral
Aneurysmatic Subarachnoid Haemorrhage
First Posted Date
2025-07-03
Last Posted Date
2025-07-03
Lead Sponsor
The First Affiliated Hospital with Nanjing Medical University
Target Recruit Count
200
Registration Number
NCT07050381
Locations
🇨🇳

Jiangsu Province Hospital, Nanjing, Jiangsu, China

🇨🇳

the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China

A Study Comparing the Necessity of a Second Transurethral Resection in High-Risk Non-Muscle-Invasive Bladder Cancer Patients With Negative Results From Post-Initial Resection Urine Genome-Wide Low-Depth Sequencing

Not Applicable
Recruiting
Conditions
Non Muscle Invasive Bladder Cancer
First Posted Date
2025-06-25
Last Posted Date
2025-06-25
Lead Sponsor
The First Affiliated Hospital with Nanjing Medical University
Target Recruit Count
428
Registration Number
NCT07036731
Locations
🇨🇳

The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, Nanjing, Jiangsu, China

  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 88
  • Next

News

No news found
© Copyright 2025. All Rights Reserved by MedPath